New research suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle programs.
Published data in a major medical journal points out that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these treatments need to be informed of the potential of rapid weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about 18 months.
Comparing Therapies
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
Researchers point out that individuals who lose weight through lifestyle changes alone generally see a slower creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Nutrition scientists suggest the way of the injections is key to understanding the heightened rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the high risk of weight regain, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like hypertension.
User Accounts
People who have stopped the jabs describe a powerful return of cravings.
"It felt as if a trigger activating and you become extremely hungry," recalled a patient.
The struggle is worsened if users have not developed lasting lifestyle or habit changes during treatment.
Widespread Use
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on ongoing lifestyle support.
